SciELO - Scientific Electronic Library Online

 
vol.21 issue1Comparative study of survey methods for atopy in patients with rhinitis (ImmunoCAP® Rapid versus Phadiatop® and skin prick tests) author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Portuguesa de Imunoalergologia

Print version ISSN 0871-9721

Abstract

DIAS, José Geraldo; MENDES, Ana; PEDRO, Elisa  and  BARBOSA, Manuel Pereira. Asthma and atopic eczema in a child: Successful treatment with omalizumab. Rev Port Imunoalergologia [online]. 2013, vol.21, n.1, pp.49-53. ISSN 0871-9721.

Background: Omalizumab is approved as add -on therapy in severe allergic asthma above 5 years old. Case report: Ten-year-old boy with allergic asthma and atopic eczema, which worsened at 8 years old and remained uncontrolled (ACT-11; SCORAD-70,9), despite treatment with inhaled corticosteroids (IC), long acting β 2 agonist, leukotriene receptor antagonist and topical corticosteroid and immunomodulator. Started oral corticosteroids (OC), with clinical improvement, which disappeared when OC were reduced. For this reason, he started omalizumab 150 mg/month. OC were suspended after two months, is under treatment with omalizumab for 27 months and since 16 weeks of treatment has controlled asthma (ACT-24), with reduction of the dose of IC, rescue medication use and frequency and severity of exacerbations, and improvement of atopic eczema (SCORAD-12,3). Discussion: Omalizumab, as add-on therapy, was effective in a child with severe allergic asthma and atopic dermatitis, allowing OC’ suspension and control of asthma and atopic eczema.

Keywords : Asthma; atopic eczema; child; omalizumab.

        · abstract in Portuguese     · text in Portuguese     · Portuguese ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License